Health Care & Life Sciences » Pharmaceuticals | Mitsubishi Tanabe Pharma Corp.

Mitsubishi Tanabe Pharma Corp. | Cash Flow

Fiscal year is April-March. All values JPY Millions.
2014
2015
2016
2017
2018
2019
Net Income before Extraordinaries
72,441
62,677
83,255
96,059
78,764
50,439
Depreciation, Depletion & Amortization
19,759
19,945
10,336
10,454
11,535
11,529
Other Funds
83
1,771
2,447
2,519
344
29,867
Funds from Operations
57,002
65,648
65,891
74,571
76,392
32,101
Changes in Working Capital
12,894
2,519
14,951
14,786
9,449
9,359
Net Operating Cash Flow
69,896
68,167
80,842
59,785
66,943
41,460
Capital Expenditures
14,340
14,479
29,190
20,929
28,450
Sale of Fixed Assets & Businesses
2,919
13,154
5,788
5,381
22,915
Purchase/Sale of Investments
29,406
37,947
22,247
5,308
41,657
Net Investing Cash Flow
24,344
59,834
42,213
10,566
13,769
Cash Dividends Paid - Total
22,439
22,439
24,683
26,927
37,017
Issuance/Reduction of Debt, Net
843
1,216
-
-
-
Net Financing Cash Flow
21,098
21,884
22,236
24,408
37,910
Net Change in Cash
26,212
11,620
15,582
24,304
13,807
Free Cash Flow
57,594
55,191
68,952
45,514
60,527
Net Assets from Acquisitions
21,589
-
-
-
119,724
Other Sources
-
47
3,436
-
70,000
Change in Capital Stock
581
-
-
-
549
Exchange Rate Effect
1,758
1,931
811
507
1,457
Other Uses
20,740
20,609
-
326
167

About Mitsubishi Tanabe Pharma

View Profile
Address
3-2-10 Dosho-machi
Osaka Osaka 541
Japan
Employees -
Website http://www.mt-pharma.co.jp
Updated 07/08/2019
Mitsubishi Tanabe Pharma Corp. engages in the research, development, manufacture, and sale of pharmaceutical products. Its products include Remicade, Ceredist, Talion, Kremezin, Maintate, Simponi, Lexapro, Tenelia, Tetrabik, and Imusera. The company operates through Pharmaceuticals segment.

StatInvestor

Privacy Policy
Feedback

© 2025 StatInvestor All Rights Reserved.